RSS   Newsletter   Contact   Advertise with us

Sangamo BioSciences appoints Edward R. Conner as CMO

Staff Writer | Richmond, Ca., USA | December 5, 2016
SangamoDecember 5, 2016, Richmond, Ca., USA - Sangamo BioSciences, a clinical stage biopharmaceutical company, has appointed Edward R. Conner as senior vice president and chief medical officer.
Dr. Conner joins Sangamo from Ultragenyx Pharmaceutical Inc., a biopharmaceutical company developing novel products for the treatment of rare and ultra-rare diseases, where he served as vice president, clinical science.

From 2013 to 2014 Dr. Conner served as BioMarin Pharmaceutical Inc.'s senior medical director and led protocol development and regulatory interaction for its global phase 3 program in Pompe disease.

He worked for five years at Genentech in various clinical leadership roles.

Dr. Conner earned his M.D. from the University of California San Francisco.

He completed residency training in internal medicine at the University of Michigan, and was a fellow in clinical immunology and allergic diseases at Johns Hopkins School of Medicine.

Dr. Conner was awarded a B.S Biology, cum laude, from Duke University.